CompletedNot Applicable

Re-Irradiation of Progressive or Recurrent DIPG

Australia27 participantsStarted 2017-04-15

Plain-language summary

This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Each site may accept a patient on study of any age that they have permission to treat and follow on study per their institutional policy.
✓. The patient has no evidence of metastases on cranial or spinal MR imaging
✓. The patient has received RT in the past, given to a total cumulative dose of \<60 Gy; prior radiation using opposed lateral fields, conformal 3-D fields, IMRT or using protons is acceptable
✓. At least 180 days have elapsed from the last day of primary RT for DIPG
✓. The patient has recovered from all acute and subacute toxicities of prior RT and of chemotherapy, if chemotherapy was utilized in the past
✓. The patient has been off all anti-tumour therapy for at least 14 days
✓. The patient has a Lansky score of 40% or higher
✓. The patient has a life expectancy anticipated to be at least 8 weeks with treatment using re-irradiation, with or without dexamethasone

✕. Females who are pregnant, due to risks from rRT on the developing fetus.
✕. Any patient with a condition that prohibits the planned delivery of rRT as prescribed in this study.
✕. Patients who are receiving any other clinical trial of an anti-tumour intervention

second progression-free survival

Timeframe: up to 18 months from the start of re-irradiation

NCT IDNCT03126266

SponsorUniversity of Calgary

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-20